Elena Losina1, Karen C Smith2, A David Paltiel3, Jamie E Collins1, Lisa G Suter4, David J Hunter5, Jeffrey N Katz1, Stephen P Messier6. 1. Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Research Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Research Center, Brigham and Women's Hospital, Boston, Massachusetts. 3. Yale School of Public Health, Yale University, New Haven, Connecticut. 4. Yale School of Medicine Yale University, New Haven, Connecticut. 5. Institute of Bone and Joint Research, Kolling Institute, University of Sydney and Royal North Shore Hospital, Sydney, Australia. 6. Wake Forest University, Winston-Salem, North Carolina.
Abstract
OBJECTIVE: The Intensive Diet and Exercise for Arthritis (IDEA) trial showed that an intensive diet and exercise (D+E) program led to a mean 10.6-kg weight reduction and 51% pain reduction in patients with knee osteoarthritis (OA). The aim of the current study was to investigate the cost-effectiveness of adding this D+E program to treatment in overweight and obese (body mass index >27 kg/m2 ) patients with knee OA. METHODS: We used the Osteoarthritis Policy Model to estimate quality-adjusted life-years (QALYs) and lifetime costs for overweight and obese patients with knee OA, with and without the D+E program. We evaluated cost-effectiveness with the incremental cost-effectiveness ratio (ICER), a ratio of the differences in lifetime cost and QALYs between treatment strategies. We considered 3 cost-effectiveness thresholds: $50,000/QALY, $100,000/QALY, and $200,000/QALY. Analyses were conducted from health care sector and societal perspectives and used a lifetime horizon. Costs and QALYs were discounted at 3% per year. D+E characteristics were derived from the IDEA trial. Deterministic and probabilistic sensitivity analyses (PSAs) were used to evaluate parameter uncertainty and the effect of extending the duration of the D+E program. RESULTS: In the base case, D+E led to 0.054 QALYs gained per person and cost $1,845 from the health care sector perspective and $1,624 from the societal perspective. This resulted in ICERs of $34,100/QALY and $30,000/QALY. In the health care sector perspective PSA, D+E had 58% and 100% likelihoods of being cost-effective with thresholds of $50,000/QALY and $100,000/QALY, respectively. CONCLUSION: Adding D+E to usual care for overweight and obese patients with knee OA is cost-effective and should be implemented in clinical practice.
OBJECTIVE: The Intensive Diet and Exercise for Arthritis (IDEA) trial showed that an intensive diet and exercise (D+E) program led to a mean 10.6-kg weight reduction and 51% pain reduction in patients with knee osteoarthritis (OA). The aim of the current study was to investigate the cost-effectiveness of adding this D+E program to treatment in overweight and obese (body mass index >27 kg/m2 ) patients with knee OA. METHODS: We used the Osteoarthritis Policy Model to estimate quality-adjusted life-years (QALYs) and lifetime costs for overweight and obesepatients with knee OA, with and without the D+E program. We evaluated cost-effectiveness with the incremental cost-effectiveness ratio (ICER), a ratio of the differences in lifetime cost and QALYs between treatment strategies. We considered 3 cost-effectiveness thresholds: $50,000/QALY, $100,000/QALY, and $200,000/QALY. Analyses were conducted from health care sector and societal perspectives and used a lifetime horizon. Costs and QALYs were discounted at 3% per year. D+E characteristics were derived from the IDEA trial. Deterministic and probabilistic sensitivity analyses (PSAs) were used to evaluate parameter uncertainty and the effect of extending the duration of the D+E program. RESULTS: In the base case, D+E led to 0.054 QALYs gained per person and cost $1,845 from the health care sector perspective and $1,624 from the societal perspective. This resulted in ICERs of $34,100/QALY and $30,000/QALY. In the health care sector perspective PSA, D+E had 58% and 100% likelihoods of being cost-effective with thresholds of $50,000/QALY and $100,000/QALY, respectively. CONCLUSION: Adding D+E to usual care for overweight and obesepatients with knee OA is cost-effective and should be implemented in clinical practice.
Authors: Elizabeth W Paxton; Robert S Namba; Gregory B Maletis; Monti Khatod; Eric J Yue; Mark Davies; Richard B Low; Ronald W B Wyatt; Maria C S Inacio; T Ted Funahashi Journal: J Bone Joint Surg Am Date: 2010-12 Impact factor: 5.284
Authors: Christopher P Cannon; Sean P Curtis; Garret A FitzGerald; Henry Krum; Amarjot Kaur; James A Bolognese; Alise S Reicin; Claire Bombardier; Michael E Weinblatt; Désirée van der Heijde; Erland Erdmann; Loren Laine Journal: Lancet Date: 2006-11-18 Impact factor: 79.321
Authors: Gerry Richardson; Neil Hawkins; Christopher James McCarthy; Pauline Mary Mills; Rachel Pullen; Christopher Roberts; Alan Silman; Jacqueline Ann Oldham Journal: Int J Technol Assess Health Care Date: 2006 Impact factor: 2.188
Authors: Søren T Skou; Ewa M Roos; Mogens B Laursen; Michael S Rathleff; Lars Arendt-Nielsen; Ole Simonsen; Sten Rasmussen Journal: N Engl J Med Date: 2015-10-22 Impact factor: 91.245
Authors: T E McAlindon; R R Bannuru; M C Sullivan; N K Arden; F Berenbaum; S M Bierma-Zeinstra; G A Hawker; Y Henrotin; D J Hunter; H Kawaguchi; K Kwoh; S Lohmander; F Rannou; E M Roos; M Underwood Journal: Osteoarthritis Cartilage Date: 2014-01-24 Impact factor: 6.576
Authors: Kim L Bennell; Catherine Keating; Belinda J Lawford; Alexander J Kimp; Thorlene Egerton; Courtney Brown; Jessica Kasza; Libby Spiers; Joseph Proietto; Priya Sumithran; Jonathan G Quicke; Rana S Hinman; Anthony Harris; Andrew M Briggs; Carolyn Page; Peter F Choong; Michelle M Dowsey; Francis Keefe; Christine Rini Journal: BMC Musculoskelet Disord Date: 2020-03-12 Impact factor: 2.362
Authors: Michael W Seward; Brielle J Antonelli; Nancy Giunta; Richard Iorio; Wolfgang Fitz; Jeffrey K Lange; Vivek M Shah; Antonia F Chen Journal: J Orthop Surg Res Date: 2020-11-13 Impact factor: 2.359
Authors: Emma E Williams; Jeffrey N Katz; Valia P Leifer; Jamie E Collins; Tuhina Neogi; Lisa G Suter; Bruce Levy; Alexander Farid; Clare E Safran-Norton; A David Paltiel; Elena Losina Journal: ACR Open Rheumatol Date: 2022-07-21
Authors: J K Sullivan; J Huizinga; R R Edwards; D J Hunter; T Neogi; E Yelin; J N Katz; E Losina Journal: Osteoarthritis Cartilage Date: 2020-11-07 Impact factor: 6.576
Authors: Codie A Primeau; Bryn O Zomar; Lyndsay E Somerville; Ishita Joshi; J Robert Giffin; Jacquelyn D Marsh Journal: Orthop J Sports Med Date: 2021-03-09